Original Research Article
Performance of FDG PET for Detection of Alzheimer’s Disease in Two Independent Multicentre Samples (NEST-DD and ADNI)Haense C.a, b · Herholz K.b · Jagust W.J.c · Heiss W.D.a
aMax Planck Institute for Neurological Research, Cologne, Germany; bWolfson Molecular Imaging Centre, University of Manchester, Manchester, UK; cSchool of Public Health and Helen Wills Neuroscience Institute, University of California, Berkeley, Calif., USA
Prof. Karl Herholz
University of Manchester, Wolfson Molecular Imaging Centre
27 Palatine Road
Manchester M20 3LJ (UK)
Tel. +44 161 275 0000, Fax +44 161 275 0003, E-Mail firstname.lastname@example.org
Do you have an account?
Aim: We investigated the performance of FDG PET using an automated procedure for discrimination between Alzheimer’s disease (AD) and controls, and studied the influence of demographic and technical factors. Methods: FDG PET data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [102 controls (76.0 ± 4.9 years) and 89 AD patients (75.7 ± 7.6 years, MMSE 23.5 ± 2.1) and the Network for Standardisation of Dementia Diagnosis (NEST-DD) [36 controls (62.2 ± 5.0 years) and 237 AD patients (70.8 ± 8.3 years, MMSE 20.9 ± 4.4). The procedure created t-maps of abnormal voxels. The sum of t-values in predefined areas that are typically affected by AD (AD t-sum) provided a measure of scan abnormality associated with a preset threshold for discrimination between patients and controls. Results: AD patients had much higher AD t-sum scores compared to controls (p < 0.01), which were significantly related to dementia severity (ADNI: r = –0.62, p < 0.01; NEST-DD: r = –0.59, p < 0.01). Early-onset AD patients had significantly higher AD t-sum scores than late-onset AD patients (p < 0.01). Differences between databases were mainly due to different age distributions. The predefined AD t-sum threshold yielded a sensitivity and specificity of 83 and 78% in ADNI and 78 and 94% in NEST-DD, respectively. Conclusion: The automated FDG PET analysis procedure provided good discrimination power, and was most accurate for early-onset AD.
© 2009 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.